Patent application number | Description | Published |
20080227794 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones - Compounds of formula I: | 09-18-2008 |
20080227824 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders - The present invention is directed to novel compounds of formula (I)/(II)/(III), their use in therapy and pharmaceutical compositions comprising said novel compounds. | 09-18-2008 |
20080306077 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 - Compounds of Formula I: | 12-11-2008 |
20080306088 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 - Compounds of Formula I: | 12-11-2008 |
20080312240 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists - The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: | 12-18-2008 |
20080312246 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists - The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: | 12-18-2008 |
20080318999 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators - The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 12-25-2008 |
20090012089 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators - The present invention is directed to compounds of Formula I: | 01-08-2009 |
20090023711 | Piperazines and Piperidines as Mglur5 Potentiators - Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: | 01-22-2009 |
20090054491 | Use - The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity. | 02-26-2009 |
20090069340 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders - Compounds of Formula (I), wherein R | 03-12-2009 |
20090111830 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - The present invention is directed to compounds of formula I: | 04-30-2009 |
20090124578 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - Compounds in accord with Formula I: | 05-14-2009 |
20090149505 | Metabotropic Glutamate Receptor-Potentiating Isoindolones - Compounds of Formula I: | 06-11-2009 |
20090192169 | Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators - Compounds of Formula I: | 07-30-2009 |
20100016403 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 01-21-2010 |
20100280082 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators - Compounds of Formula (I) wherein R | 11-04-2010 |
20100317674 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones - Compounds of formula I: | 12-16-2010 |
20110053953 | AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613 - Compounds of formula I: wherein R | 03-03-2011 |
20110166155 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - The present invention is directed to compounds of formula I: | 07-07-2011 |
20120065176 | TREATMENT OF MUSCLE DISEASE CHARACTERIZED BY INSULIN RESISTANCE - It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized by impaired insulin-dependent signaling by targeting components of the defective insulin signaling pathway. The disease or condition may be treated by administering a therapeutic agent that activates the insulin signaling pathway, in particular, therapeutic agents that act post-insulin receptor to modulate intracellular effector molecules. An exemplary modulator is metformin. Metformin may be administered alone or may be co-administered with another therapeutic agent for treating the muscle disease or condition, such as a corticosteroid. | 03-15-2012 |
20120302596 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY - Described herein are compounds with affinity for the 5-HT | 11-29-2012 |
20140018549 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS - Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias, wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R | 01-16-2014 |